Image de couverture de livre

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	The Brown University Psychopharmacology Update
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Cohort study suggests benefit of earlier initiation of clozapine
Publié: (2025)

Study suggests benefit of continuing antipsychotic during pregnancy
Publié: (2025)

Trial suggests e‐cigarettes can be effective for smoking cessation
Publié: (2024)

The demise of metformin and the rise of the GLP‐1 agonists
par: Lawrence H. Price
Publié: (2026)

GLP‐1 receptor agonists not associated with increased suicidality
Publié: (2024)

Review of GLP‐1 trials finds low incidence of suicide risk
Publié: (2025)

Review finds GLP‐1s have favorable psychiatric safety profile
Publié: (2025)

GLP‐1s did not increase suicide risk in patients with type 2 diabetes
Publié: (2025)

Meta‐analysis suggests safety of methylphenidate, atomoxetine in pregnancy
Publié: (2025)

Analysis suggests risk of suicidal ideation associated with semaglutide
Publié: (2024)

Data on prescription stimulant misuse suggest need for closer screening
Publié: (2025)

Review suggests broad efficacy of lurasidone in reducing depressive symptoms
Publié: (2025)

Meta‐analysis suggests risk of psychosis from stimulant treatment for ADHD
Publié: (2025)

Review suggests need to monitor blood pressure in youths receiving ADHD medications
Publié: (2025)

The psychiatric benefits of cannabinoids: scarcity of evidence
par: Lawrence H. Price
Publié: (2026)

Review finds limited benefit from cannabinoids for PTSD
Publié: (2024)

Psilocybin‐assisted therapy shows range of benefits in cancer patients
Publié: (2025)

Meta‐analysis finds little benefit from cannabinoids for behavioral disorders
Publié: (2026)

Ketamine shows long‐term benefit in patients with treatment‐resistant depression
Publié: (2026)

Study of young psychiatric patients shows potential preventive benefit of doxycycline
Publié: (2026)

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia
Publié: (2024)

Neuropsychiatric effects of glucocorticoids
par: Y. W. Francis Lam
Publié: (2024)

Fremanezumab effective for comorbid migraine and depression
Publié: (2025)

Elinzanetant effective for menopausal vasomotor symptoms
Publié: (2024)

Vaccines and psychiatry: Off‐target effects
par: Lawrence H. Price
Publié: (2026)

Lumateperone effective as adjunctive therapy in patients with depression
Publié: (2025)

No protective effect of omega‐3s for youths at risk of psychosis
Publié: (2025)

Meta‐analysis finds viloxazine effective for youths with ADHD
Publié: (2025)

LAI antipsychotics show effective results in comparative analysis
Publié: (2024)

Suvorexant, lemborexant effective for preventing delirium in hospital patients
Publié: (2024)

Oral formulation of ketamine effective for treatment‐resistant depression
Publié: (2024)

Serial ketamine infusions not effective as adjunctive care for depression
Publié: (2026)

Esketamine's effects in combination with SSRI vs. SNRI show differences
Publié: (2025)

Much ado about montelukast: A side‐effects saga
par: Lawrence H. Price
Publié: (2024)

Ileus, pneumonia among most burdensome effects of clozapine treatment
Publié: (2024)

Study finds sustained effects of LSD‐assisted therapy on anxiety
Publié: (2024)

Repetitive TMS more effective than antidepressant switch in nonresponders
Publié: (2024)

Switch from antipsychotic polypharmacy to monotherapy reduces side effects
Publié: (2024)

When both treatments unblinded, psychedelics not more effective than antidepressants
Publié: (2026)

Network meta‐analysis finds dexmedetomidine broadly effective for postoperative delirium
Publié: (2026)